Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short- versus Long-Interval Zoledronic Acid Administration in Metastatic Bone Disease
TCTR20250610004Phase 3Not yet recruiting
- Sponsor
- Institute of Orthopedics, Lerdsin Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in bone metastases (2 arms), sponsored by Institute of Orthopedics, Lerdsin Hospital. Primary endpoint: Incidence of skeletal-related events. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
zoledronic acid
03
Conditions
bone metastases
Beyond the preview
Go deeper on TCTR20250610004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250610004.